Longitudinal association of dietary spermidine with hepatic function indexes and cardiometabolic traits in older adults with metabolic syndrome

Read the full article See related articles

Discuss this preprint

Start a discussion What are Sciety discussions?

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Purpose: Spermidine administration ameliorates hepatic steatosis and cardiometabolic dysfunction in animal models. However, evidence in humans remains limited. We aimed to explore the 1-year longitudinal associations between changes in dietary spermidine intake and hepatic function indexes and cardiometabolic traits in overweight and obese older adults with metabolic syndrome. Methods: We used baseline and 1-year follow-up data from 2664 participantsfrom the PREDIMED-Plus trial. Dietary spermidine intake was estimated using a semi-quantitative food frequency questionnaire. Time series clustering identified temporal patterns of 1-year change in spermidine intake. Linear mixed-effects models assessed the associations between spermidine intake clusters and changes in hepatic and cardiometabolic markers. Results : Three distinct spermidine intake patterns were identified across baseline, six-months and 1-year follow-up. Cluster 3, characterized by the highest baseline and increased 1-year intake, was associated with mean reductions in fatty liver index (-8.97 [-9.96 to -7.97], p-int < 0.001), hepatic steatosis index (-1.88 [-2.13 to -1.63], p-int < 0.001), alanine aminotransferase (-2.93 [-3.83 to -2.02] U/L, p-int < 0.05), aspartate aminotransferase (-1.11 [-1.76 to -0.45] U/L, p-int < 0.05) and glycated hemoglobin levels (-0.14 [-0.18 to -0.10] %, p-int < 0.01), compared to Cluster 1. Cluster 3 also showed, mean decreases in body mass index (-1.26 [-1.37 to -1.15]), waist (-3.72 [-4.11 to -3.32] cm) and hip circumference (-2.33 [-2.67 to -1.99] cm) (all p-int < 0.001). Conclusion: A 1-year increase in dietary spermidine intake was associated with improvements in hepatic function indexes and cardiometabolic traits in overweight and obese older adults with metabolic syndrome. Clinical Trial: Retrospectively registered at the International Standard Randomized Controlled Trial Registry (89898870) on 24th July 2014

Article activity feed